NCT06409195View on ClinicalTrials.gov

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Non-Melanoma Skin Cancers
Interventions
DRUG

SM-020 1% Gel

SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.

Trial Locations (1)

28207

RECRUITING

Dermatology, Laser and Vein Specialist, Charlotte

Sponsors

Lead Sponsor

DermBiont, Inc.
All Listed Sponsors
lead

DermBiont, Inc.

INDUSTRY

NCT06409195 - A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers | Biotech Hunter | Biotech Hunter